Evelo Biosciences Inc. (NASDAQ:EVLO) went up by 14.75% from its latest closing price compared to the recent 1-year high of $17.12. The company’s stock price has collected -8.04% of loss in the last five trading sessions.
Is It Worth Investing in Evelo Biosciences Inc. (NASDAQ :EVLO) Right Now?
Plus, the 36-month beta value for EVLO is at 1.74. Opinions of the stock are interesting as 5 analysts out of 6 who provided ratings for Evelo Biosciences Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $13.00, which is $15.65 above the current price. EVLO currently public float of 27.24M and currently shorts hold a 27.11% ratio of that float. Today, the average trading volume of EVLO was 330.57K shares.
EVLO’s Market Performance
EVLO stocks went down by -8.04% for the week, with a monthly jump of 1.67% and a quarterly performance of -43.34%, while its annual performance rate touched -88.96%. The volatility ratio for the week stands at 10.33% while the volatility levels for the past 30 days are set at 14.73% for Evelo Biosciences Inc. The simple moving average for the period of the last 20 days is 1.23% for EVLO stocks with a simple moving average of -60.89% for the last 200 days.
Analysts’ Opinion of EVLO
Many brokerage firms have already submitted their reports for EVLO stocks, with Chardan Capital Markets repeating the rating for EVLO by listing it as a “Buy.” The predicted price for EVLO in the upcoming period, according to Chardan Capital Markets is $12 based on the research report published on November 01st of the previous year 2021.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see EVLO reach a price target of $28. The rating they have provided for EVLO stocks is “Overweight” according to the report published on June 23rd, 2021.
Jefferies gave a rating of “Buy” to EVLO, setting the target price at $18 in the report published on April 12th of the previous year.
EVLO Trading at -5.94% from the 50-Day Moving Average
After a stumble in the market that brought EVLO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.74% of loss for the given period.
Volatility was left at 14.73%, however, over the last 30 days, the volatility rate increased by 10.33%, as shares surge +11.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -43.88% lower at present.
During the last 5 trading sessions, EVLO fell by -1.93%, which changed the moving average for the period of 200-days by -79.14% in comparison to the 20-day moving average, which settled at $2.0841. In addition, Evelo Biosciences Inc. saw -69.85% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at EVLO starting from McHale Duncan, who purchase 34,246 shares at the price of $1.46 back on May 27. After this action, McHale Duncan now owns 34,246 shares of Evelo Biosciences Inc., valued at $49,999 using the latest closing price.
Darzi Lord Ara, the Director of Evelo Biosciences Inc., purchase 342,465 shares at $1.46 during a trade that took place back on May 27, which means that Darzi Lord Ara is holding 342,465 shares at $499,999 based on the most recent closing price.
Stock Fundamentals for EVLO
Equity return is now at value -569.20, with -121.30 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 4.09.